• Explore /
  • Poster
  • / Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).

Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).

Abstract Poster

Authors

Christopher Hoimes

Christopher J. Hoimes

Duke Cancer Center, Durham, NC

Christopher J. Hoimes , Thomas W. Flaig , Sandy Srinivas , Nataliya Mar , Daniel P. Petrylak , Peter H. O'Donnell , Mehmet Asim Bilen , Carolyn Sasse , Yao Yu , Matthew Birrenkott , Jonathan E. Rosenberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03288545

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS587)

DOI

10.1200/JCO.2022.40.6_suppl.TPS587

Abstract #

TPS587

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Terence W. Friedlander

First Author: Nataliya Mar

First Author: Peter H. O'Donnell

First Author: Christopher J. Hoimes